法国社区获得性尿路感染大肠埃希菌的甲氧苄啶敏感性。
Trimethoprim susceptibility in E. coli community-acquired urinary tract infections in France.
机构信息
Laboratoire de microbiologie, centre hospitalier Roubaix, 59100 Roubaix, France.
Conseil scientifique de l'observatoire national de l'épidémiologie de la résistance bactérienne aux antibiotiques, 75006 Paris, France; Inserm, U1135, centre d'immunologie et des maladies infectieuses, CIMI, Team E13 (Bactériologie), Sorbonne Universités, UPMC université Paris 06, CR7, 75005 Paris, France; Bactériologie-hygiène, hôpitaux universitaires Pitié-Salpêtrière-Charles-Foix, AP-HP, 75013 Paris, France.
出版信息
Med Mal Infect. 2018 Sep;48(6):410-413. doi: 10.1016/j.medmal.2018.03.010. Epub 2018 Apr 16.
OBJECTIVES
Trimethoprim has been recently included in the French guidelines for the treatment of urinary tract infections, but no epidemiological data supports its use. We aimed to determine the trimethoprim susceptibility of Escherichia coli isolates responsible for community-acquired urinary tract infections in women of childbearing age.
MATERIALS AND METHODS
We conducted a national prospective survey. A total of 350 strains of E. coli isolated from urines in 35 laboratories were included. Antibiotic susceptibility testing was performed in each laboratory.
RESULTS
We reported a susceptibility rate of 78%, and a similar clinical categorization between trimethoprim and cotrimoxazole for 97.4% of isolates. We pointed out an association between resistance to trimethoprim and other antibiotic classes.
CONCLUSION
The results support trimethoprim as a second-line therapy based on antibiotic susceptibility testing results. We confirm that trimethoprim and cotrimoxazole susceptibility rates are very close.
目的
最近，法国指南中已将甲氧苄啶纳入治疗尿路感染的方案中，但没有流行病学数据支持其使用。我们旨在确定引起育龄妇女社区获得性尿路感染的大肠埃希菌分离株对甲氧苄啶的敏感性。
材料与方法
我们进行了一项全国性前瞻性调查。共纳入 35 个实验室从尿液中分离的 350 株大肠埃希菌。在每个实验室进行抗生素敏感性试验。
结果
我们报告的敏感性率为 78%，97.4%的分离株对甲氧苄啶和复方磺胺甲噁唑的临床分类相似。我们指出了对甲氧苄啶的耐药性与其他抗生素类别的关联。
结论
这些结果支持根据抗生素敏感性试验结果将甲氧苄啶作为二线治疗。我们证实甲氧苄啶和复方磺胺甲噁唑的敏感性率非常接近。
Zotero 插件